BNP PARIBAS ARBITRAGE/PUT/MODERNA/120/0.01/20.12.24 Stock

Warrant

P216D1

NLBNPIT216D1

Real-time Borsa Italiana 09:01:35 2024-06-27 am EDT
0.1545 EUR +3.34% Intraday chart for BNP PARIBAS ARBITRAGE/PUT/MODERNA/120/0.01/20.12.24
Current month+46.57%
1 month+128.24%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-27 0.1545 +3.34%
24-06-26 0.1495 +42.38%
24-06-25 0.105 -1.41%
24-06-24 0.1065 -10.13%
24-06-21 0.1185 +1.28%

Real-time Borsa Italiana

Last update June 27, 2024 at 09:01 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellPUT
Underlying MODERNA, INC.
IssuerLogo Issuer BNP Paribas BNP Paribas
P216D1
ISINNLBNPIT216D1
Date issued 2024-03-26
Strike 120 $
Maturity 2024-12-20 (176 Days)
Parity 100 : 1
Emission price-
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.273
Lowest since issue 0.063
Spread 0.0145
Spread %8.92%

Company Profile

Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
More about the company

Ratings for Moderna, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Moderna, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
122.4 USD
Average target price
145.9 USD
Spread / Average Target
+19.11%
Consensus
  1. Stock Market
  2. Warrants
  3. P216D1 Warrant